Amneal to launch $735 million term loan B repricing on Wednesday

By Sara Rosenberg

New York, June 15 – Amneal Pharmaceuticals LLC is scheduled to hold a lender call on Wednesday to launch a repricing of its $735 million term loan B, according to a market source.

GE Capital Markets is the lead on the deal.

The repricing is talked at Libor plus 325 basis point with a 1% Libor floor, a par issue price and 101 soft call protection for six months, the source said.

Commitments are due on June 24.

Through this transaction, pricing on the term loan B will be reduced from Libor plus 400 bps with a 1% Libor floor.

Pricing on the company’s $200 million covenant-light incremental term loan B-2 that was syndicated in March will be unchanged at Libor plus 350 bps with a 1% Libor floor.

Amneal Pharmaceuticals is a Bridgewater, N.J.-based manufacturer of generic pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.